Comparative analysis of the predictive power of different endothelial progenitor cell phenotypes on cardiovascular outcome

Table 1 Baseline characteristics of the patient population and drug treatment n (%)

Characteristics	n = 76
Demographic data
Male/female	53 (70)/23 (30)
Median age (range, yr)	69 (42-86)
Current smoker	35 (46)
Comorbidities
Hypertension	48 (63)
Diabetes mellitus	20 (26)
Hyperlipidemia	39 (51)
Peripheral vascular disease	4 (5.3)
CVA/TIA	5 (6.3)
Drug treatment
Statin	71 (93.4)
Beta blocker	71 (93.4)
ACEI/ARB	75 (99)
Spironolactone	40 (69)
Diuretics	9 (12)
CCBs	5 (6.6)
Nitrates	12 (16)

CVA: Cardiovascular accident; TIA: Transient ischemic attack; ACEI: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; CCB: Calcium channel blocker.

Table 2 Different endothelial progenitor cell combinations stratified by outcomes n (%)

	Total mortality	Recurrent UA/MI	ADHF	Any MACE
CD34+CD133+ = 0 (n = 7)	1 (14.3)	7 (100)	1 (14.3)	7 (100)
CD34+CD133+ > 0 (n = 69)	6 (8.7)	43 (62.3)	12 (17.4)	47 (68.1)
CD34+KDR+ = 0 (n = 57)	6 (10.5)	40 (70.2)	11 (19.3)	43 (75.4)
CD34+KDR+ > 0 (n = 17)	1 (5.3)	10 (52.6)	2 (10.5)	11 (57.9)
CD133+KDR+ = 0 (n = 57)	6 (10.5)	41 (71.9)	12 (21.1)	44 (77.2)
CD133+KDR+ > 0 (n = 19)	1 (5.3)	9 (47.4)	1 (5.3)	10 (52.6)

UA: Unstable angina; MI: Myocardial infarction; ADHF: Acute decompensated heart failure; MACE: Major adverse cardiac event.